Navigating Highmark Skyrizi Prior Authorization Requirements

Successfully managing Highmark Skyrizi prior authorization is critical for timely patient access to this specialty medication. Klivira provides the automation and insights needed to navigate these complex requirements efficiently.

For revenue cycle directors, prior authorization coordinators, and IT integration leads, the process of securing approval for specialty drugs like Skyrizi (risankizumab) from payers such as Highmark presents unique challenges. Understanding payer-specific submission channels, policy access, and regulatory compliance is paramount to minimizing delays and denials, ensuring patients receive necessary care without administrative bottlenecks.

Skyrizi (Risankizumab): An Overview for Prior Authorization

Skyrizi (risankizumab) is an IL-23 inhibitor manufactured by AbbVie, indicated for treating conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease. As a high-cost specialty medication, Skyrizi consistently requires prior authorization to ensure medical necessity and appropriate utilization according to payer guidelines, including those set by Highmark.

Highmark's Prior Authorization Channels for Skyrizi

For medical-benefit prior authorization submissions to Highmark, providers in Pennsylvania, West Virginia, Delaware, and Western New York typically route requests through Availity Essentials. Highmark also supports X12 278 transactions for impacted medical procedures via clearinghouses. For pharmacy-benefit Skyrizi, the specific Pharmacy Benefit Manager (PBM) relationship Highmark utilizes should be verified, as BCBS plans may partner with various PBMs.

Accessing Highmark Utilization Management Policies for Skyrizi

Highmark publishes its comprehensive medical policies and clinical utilization management guidelines on its provider website. Accessing these resources is essential for understanding the specific criteria for Skyrizi (risankizumab) approval, including any formulary tiers, step therapy requirements, or quantity limits. Direct consultation of the most current payer policies is crucial for accurate submission and compliance.

Highmark Prior Authorization Turnaround Times and Regulatory Considerations

Prior authorization turnaround times for Highmark Skyrizi submissions are subject to state-mandated minimums in each of its service areas (PA, WV, DE, NY), with specific rules set by state insurance regulators. Additionally, Highmark's Medicare Advantage, Medicaid managed-care, and any Qualified Health Plan (QHP) lines on the Federally Facilitated Marketplace (FFM) are impacted by the interoperability and prior authorization requirements outlined in CMS-0057-F.

Optimizing Highmark Skyrizi PA with Klivira

Klivira streamlines the Highmark Skyrizi prior authorization process by integrating directly with EMRs and payer portals, including Availity. Our platform automates data extraction, submission via X12 278 or payer-specific ePA, and status tracking for risankizumab and other specialty medications. This reduces manual effort, accelerates time to decision, and allows provider teams to focus on patient care rather than administrative burdens.

Frequently asked questions

What are the primary submission channels for Highmark Skyrizi prior authorization?

For medical benefits, Highmark typically directs prior authorization submissions through Availity Essentials. X12 278 transactions are also accepted via clearinghouses. For pharmacy benefits, the specific PBM Highmark uses should be confirmed as this can vary.

Where can I find Highmark's medical policies for Skyrizi (risankizumab)?

Highmark publishes its medical policies and clinical utilization management guidelines on its dedicated provider website. It is crucial to consult these resources directly for the most current criteria regarding Skyrizi approval.

Do state regulations impact Highmark Skyrizi prior authorization turnaround times?

Yes, prior authorization turnaround times for Highmark Skyrizi are governed by state-mandated minimums in each of its operational states: Pennsylvania, West Virginia, Delaware, and New York. These regulations are enforced by respective state insurance departments.

Is Highmark impacted by CMS-0057-F for prior authorizations?

Yes, Highmark's Medicare Advantage, Medicaid managed-care, and any Qualified Health Plan (QHP) lines on the Federally Facilitated Marketplace (FFM) are subject to the interoperability and prior authorization requirements detailed in CMS-0057-F.

How does Klivira assist with Highmark Skyrizi prior authorizations?

Klivira automates the prior authorization workflow for Highmark Skyrizi by integrating with EMRs and payer portals like Availity. Our platform handles data extraction, submission (including X12 278), and status tracking, aiming to reduce manual tasks and expedite approval times for risankizumab.